Literature DB >> 21376668

MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer.

Cathy A Andorfer1, Brian M Necela, E Aubrey Thompson, Edith A Perez.   

Abstract

Recognition that breast cancer is a heterogeneous disease in which each patient's tumor has specific characteristics has led to a search for biomarkers and combinations of markers (signatures) to improve the diagnosis, prognostic classification and prediction of therapeutic benefit versus toxicity for individual tumors and patients. Many microRNAs (miRNAs) are aberrantly expressed in cancer and seem to influence tumor behavior and progression. miRNAs have great potential to evolve into effective biomarkers in the clinic because of their extreme stability and ease of detection. However, there are several major technical challenges as well as numerous discrepancies among currently reported miRNA signatures. In this review, we discuss the use of miRNA signatures for breast cancer treatment and discuss the challenges in the field.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376668     DOI: 10.1016/j.molmed.2011.01.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  71 in total

Review 1.  Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms.

Authors:  Stéphanie Bianco; Nicolas Gévry
Journal:  Transcription       Date:  2012-07-01

Review 2.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

3.  Screening biomarkers of prostate cancer by integrating microRNA and mRNA microarrays.

Authors:  Jiayu Feng; Chibing Huang; Xinwei Diao; Minqi Fan; Pingxian Wang; Ya Xiao; Xiao Zhong; Ronghua Wu
Journal:  Genet Test Mol Biomarkers       Date:  2013-08-28

4.  MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Authors:  Lei Huo; Yan Wang; Yun Gong; Savitri Krishnamurthy; Jing Wang; Lixia Diao; Chang-Gong Liu; Xiuping Liu; Feng Lin; William F Symmans; Wei Wei; Xinna Zhang; Li Sun; Ricardo H Alvarez; Naoto T Ueno; Tamer M Fouad; Kenichi Harano; Bisrat G Debeb; Yun Wu; James Reuben; Massimo Cristofanilli; Zhuang Zuo
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

Review 5.  MicroRNA expression profiling in archival tissue specimens: methods and data processing.

Authors:  Thomas Streichert; Benjamin Otto; Ulrich Lehmann
Journal:  Mol Biotechnol       Date:  2012-02       Impact factor: 2.695

6.  MicroRNAs as potential clinical biomarkers: emerging approaches for their detection.

Authors:  S K Srivastava; A Bhardwaj; S J Leavesley; W E Grizzle; S Singh; A P Singh
Journal:  Biotech Histochem       Date:  2013-01-07       Impact factor: 1.718

Review 7.  Pattern recognition for predictive, preventive, and personalized medicine in cancer.

Authors:  Tingting Cheng; Xianquan Zhan
Journal:  EPMA J       Date:  2017-03-09       Impact factor: 6.543

8.  The Upregulation of hsa-mir-181b-1 and Downregulation of Its Target CYLD in the Late-Stage of Tumor Progression of Breast Cancer.

Authors:  Alireza Andalib; Shadi Rashed; Moein Dehbashi; Jamshid Hajati; Farshid Noorbakhsh; Mazdak Ganjalikhani-Hakemi
Journal:  Indian J Clin Biochem       Date:  2019-03-21

9.  Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles.

Authors:  Enrica Calura; Paolo Martini; Gabriele Sales; Luca Beltrame; Giovanna Chiorino; Maurizio D'Incalci; Sergio Marchini; Chiara Romualdi
Journal:  Nucleic Acids Res       Date:  2014-05-06       Impact factor: 16.971

Review 10.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.